688336 Sunshine Guojian Pharmaceutical
- 17.54
- -0.18-1.02%
Sunshine Guojian Pharmaceutical News
Sunshine Guojian Pharmaceutical's recombined anti-IL-4Rα humanized monoclonal antibody injection (611) for the treatment of chronic sinusitis with nasal polyps Phase II clinical study achieved the main endpoint.
Shanghai, August 9, 2024 / PRNewswire / - Today, Sunshine Guojian Pharmaceutical (Stock Code: 688336.SH) announced that the Phase II clinical study of the company's independently developed recombinant humanized anti-IL-4Rα monoclonal antibody injection (Research and development code: 611) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) has achieved its primary endpoint. The study included 100 CRSwNP subjects who were randomly assigned to the experimental drug Group A (611 300mg Q2W), experimental drug Group B (611 450mg Q4W), and safety control group at a ratio of 1: 1: 1.
Sunshine Guojian Pharmaceutical (688336.SH): SSGJ-608 has successfully achieved all efficacy endpoints in Phase III clinical trials for psoriasis, accelerating the listing process.
Sunshine Guojian Pharmaceutical (688336.SH) announced a reorganization of the injection of anti-IL-17A humanized monoclonal antibodies (...
Sunshine Guojian Pharmaceutical (688336.SH): The Phase III clinical trial of the recombinant anti-IL-17A fully humanized monoclonal antibody injection for the treatment of moderate to severe plaque psoriasis has achieved all efficacy endpoints.
On August 9th, Gelunhui reported that Sunshine Guojian Pharmaceutical (688336.SH) completed the unblinding and final statistical analysis of the key pivotal Phase III clinical trial evaluating the efficacy and safety of SSGJ-608, a humanized monoclonal antibody injection targeting IL-17A, for the treatment of moderate to severe plaque psoriasis in Chinese adults. The trial was multicenter, randomized, double-blind, and placebo-controlled. All primary efficacy endpoints (PASI75 and sPGA0/1) were met.
Sunshine Guojian Pharmaceutical (688336.SH) granted 5.1745 million restricted stocks to 92 incentive objects.
Sunshine Guojian Pharmaceutical (688336.SH) announced that the company has approved the "Restricted Stock Agreement for the year 2024"...
Declining Stock and Decent Financials: Is The Market Wrong About Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336)?
Sunshine Guojian Pharmaceutical (688336.SH) will have approximately 524 million restricted shares available for public trading starting from July 22nd.
Sunshine Guojian Pharmaceutical (688336.SH) announced that the restricted stocks to be listed and circulated this time are the initial restricted stocks of the company, which are restricted from sale...
Sunshine Guojian Pharmaceutical was awarded the A-share ESG Value Award of China Listed Companies English and Chinese by 2024.
Shanghai, July 11, 2024 / PRNewswire / - The 2024 China Capital Market Development Forum and Listing Company Forum, sponsored by China Fund News, was recently held in Shanghai. The forum also announced the winners of the 2024 China Listed Company Yinghua Demonstration Case Awards. Sunshine Guojian Pharmaceutical, a leader in innovative antibody drug development in China, won the A-share ESG Value Award. The China Listed Company Yinghua Demonstration Case Awards, initiated by China Fund News, aims to adhere to the spirit of the new "Nine Articles of the State," evaluate the comprehensive strength and value of the enterprise from a long-term and value investment perspective, and select the institutions that invest in them.
Sunshine Guojian Pharmaceutical (688336.SH) plans to distribute 0.05 yuan per share in 2023, with ex-rights and ex-dividends on June 26th.
Sunshine Guojian Pharmaceutical (688336.SH) announced that it plans to distribute a cash dividend of 0.05 yuan per share for the year 2023.
Sunshine Guojian Pharmaceutical (688336.SH) plans to launch a restricted stock incentive plan in 2024 with a grant price of 12.00 yuan/share.
Sunshine Guojian Pharmaceutical (688336.SH) released its restricted stock incentive plan (draft) for 2024. This incentive plan...
Sunshine Guojian Pharmaceutical (688336.SH): Intends to sign an exclusive license agreement with Shenyang Sunshine.
Sunshine Guojian Pharmaceutical (688336.SH) announced on June 5th that the company plans to sign an exclusive license agreement with Shenyang Sunshine, granting Shenyang Sunshine exclusive rights to the company's 706, 709, HBT-2002, QY-F10, QY-F11, QY-F07, and QY-F02 projects in the licensed area (Greater China) for the research and development, registration, improvement, production, use, sale, and promise to sell licensed products against collaborative targets for all approved indications, as well as use other intellectual property licensed by Sunshine Guojian Pharmaceutical to Shenyang Sunshine.
Here's Why We Think Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Might Deserve Your Attention Today
BeiGene (688235.SH): Revenue exceeded 5 billion yuan in the first quarter, accelerating differentiated innovation
On May 8, BeiGene (688235)'s US stock performance report for the 2024 Q1 quarter and the A-share performance report were freshly released. Financial reports show that during the reporting period, BeiGene's total revenue reached 5.359 billion yuan, up 74.8% year on year; thanks to the rapid release of the two core self-developed products, the company's global product revenue reached 5.325 billion yuan, up 89.6% year on year and 17.8% month on month, exceeding market expectations. At the same time as revenue increased dramatically, thanks to strict expense management, BeiGene's operating expenses grew slowly. Current sales and management expenses accounted for 8 percent of product revenue compared to the same period last year
Impressive Earnings May Not Tell The Whole Story For Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336)
These 4 Measures Indicate That Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Is Using Debt Safely
Revenue from main products such as Genipip surged, and the net profit of Sansheng Guojian (688336.SH) surged 171.88% in the first quarter to 91.191,000 yuan
According to Zhitong Finance App News, Sansheng Guojian (688336.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 267 million yuan, an increase of 28.72%; net profit attributable to shareholders of listed companies was 91.191,000 yuan, a year-on-year increase of 171.88%; net profit attributable to shareholders of listed companies deducted 857.583 million yuan for non-recurring profit and loss, a year-on-year increase of 203.60%; basic earnings per share were 0.15 yuan/share. In the first quarter of 2024, sales of the company's main products were good, R&D projects progressed smoothly, and internal operations continued to be efficient
Sansheng Guojian (688336.SH): Non-net profit of 857.583 million yuan in the first quarter increased 203.6% year over year
Gelonghui, April 25 | Sansheng Guojian (688336.SH) released its first quarter report. Operating revenue was 267 million yuan, up 28.72% year on year, net profit of 911.191,000 yuan, up 171.88% year on year, after deducting non-net profit of 857.583 million yuan, up 203.6% year on year, with basic earnings of 0.15 yuan per share.
Is The Market Rewarding Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Zhongtai Securities: Q1 results are about to be implemented, gradually focus on the pharmaceutical sector and individual stocks with improved Q2 performance
Zhongtai Securities said that at present, the overall market is still at a relative bottom. After experiencing a long-term correction, the pharmaceutical sector is also at multiple bottoms in terms of fundamentals, policies, and capital, and is firmly optimistic about the pharmaceutical sector market throughout the year.
Sunshine Guojian Pharmaceutical's Profit Surges Sixfold in 2023
Core products grew across the board, and Sansheng Guojian (688336.SH)'s net profit soared 497.63% to 295 million yuan in 2023, and plans to distribute 0.5 yuan for every 10 shares
Sansheng Guojian (688336.SH) released its 2023 annual report. The company achieved operating income of 10 during the reporting period...
Analysis
Price Target
No Data
